Skip to main content

Clinical Trials

Scientists at the medical school are conducting hundreds of clinical trials daily. Learn more about all our work via the Feinberg Office of Research Clinical Trials page.

Our current active protocols are listed below, searchable by disease or condition. If you have any questions about the particular study protocol, please contact the study coordinator.  For more information about the research or participation in general, please call 312-695-8643.

Trials

Peripheral Neuropathy Research Registry (PNRR)

National Peripheral Neuropathy Research Registry (PNRR), a collection of different types ofinformation, such as patient medical, family, and social histories and blood samples. Theinformation is carefully maintained so that it can be studied repeatedly in the future. The registryaims to help researchers’ access large amounts of information about people with …
National Peripheral Neuropathy Research Registry (PNRR), a collection of different types ofinformation, such as patient medical, family, and social histories and blood samples. Theinformation is carefully maintained so that it can be studied repeatedly in the future. The registryaims to help researchers’ access large amounts of information about people with PN. By using thisregistry, researchers will facilitate both basic and clinical research studies that will bring improvedunderstandings of the etiology (origination) and pathogenesis (development) of PN. They willspecifically ask why some patients with peripheral neuropathy develop neuropathic pain and othersdo not, and what the characteristics of patients with painful peripheral neuropathy are in terms oftheir symptoms, examination findings, and blood tests. Ultimately this research may result inimproved diagnosis, more effective treatments, and possibly prevention.
Inclusion criteria: 1. Diabetic Peripheral Neuropathy 2. Chemo-therapy Induced Peripheral Neuropathy 3. HIV-induced Peripheral Neuropathy 4. Idiopathic Peripheral Neuropathy; Exclusion criteria: Any other type of Peripheral Neuropathy
Ajroud-Driss, SendaAjroud-Driss, Senda
  • Map it 675 N. St. Clair St. Suite 20-100
    Chicago, IL
STU00048864
More Info
Copy

Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD)

The purpose of this study is to observe mothers with and without epilepsy, along with their children, from pregnancy until age 6 and assess the developmental and neurocognitive influence of anti-epileptic medications.
Gerard, Elizabeth ErwayGerard, Elizabeth Erway
NCT01730170 STU00070411
More Info
Copy

Non-Invasive Marker of Ovarian Reserve in Women with Epilepsy

The purpose of this study is to assess and compare AMH hormone levels in women with epilepsy vs. healthy controls, utilizing medical history questionnaires and a finger stick.
Gerard, Elizabeth ErwayGerard, Elizabeth Erway
STU00077630
More Info
Copy

NUDB 13C03: Northwestern Brain Tumor Institute Research Database

The Northwestern Brain Tumor Institute (NBTI) currently uses an electronic database to collect and store information about patients who come to the NBTI for evaluations, including diagnosis, treatment, follow-up, and/or to obtain additional opinions. This database is called the Northwestern Brain Tumor Institute Database or NBTIDB, and it …

The Northwestern Brain Tumor Institute (NBTI) currently uses an electronic database to collect and store information about patients who come to the NBTI for evaluations, including diagnosis, treatment, follow-up, and/or to obtain additional opinions. This database is called the Northwestern Brain Tumor Institute Database or NBTIDB, and it was developed to replace older paper methods for collecting and storing information.

The purpose of this study is to allow researchers involved with the NBTIDB to use data stored in it for future research studies and projects. The NBTIDB also allows researchers to track whether or not patients have agreed to allow their information to be linked to their leftover tissue samples, which are kept in the hospital’s pathology department, for future research studies.

You may be eligible to take part in the research component of the NBTIDB if you are either a new or returning patient, over the age of 18, who is being seen by one of the clinicians at the NBTI and are or will be entered into the NBTIDB, or a patient who is not coming to the NBTI for evaluation, but would still like to participate in the NBTIDB.

Kumthekar, Priya UKumthekar, Priya U
  • Map it 201 E. Huron St.
    Chicago, IL
STU00087359
More Info
Copy

Parkinson’s Disease and Movement Disorders Center Biorepository

This is a registry aimed to collect biologic and clinical information, such as blood and tissue samples, and family and medical histories from patients diagnosed with a movement disorder. The purpose of studying materials from the registry is to identify factors that either cause these neurologic conditions or increase one’…
This is a registry aimed to collect biologic and clinical information, such as blood and tissue samples, and family and medical histories from patients diagnosed with a movement disorder. The purpose of studying materials from the registry is to identify factors that either cause these neurologic conditions or increase one’s risk for developing them. Samples collected for this biorepository include a blood sample (or a saliva sample) and a skin biopsy. Participants may choose to donate one or both samples.

• Diagnosis of a movement disorder • Male or female 18 years of age or older when diagnosed • Ability to provide informed consent

Akhtar, Rizwan SmeerAkhtar, Rizwan Smeer
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
STU00091585
More Info
Copy

rTMS: A Treatment to Restore Function after Severe TBI

The purpose of this study is to address the need for targeted treatments that induce functional and structural changes in the brain, ultimately improving neurobehavioral functioning, the investigators propose examining the therapeutic effectiveness of repetitive Transcranial Magnetic Stimulation (rTMS). The objective is to improve functional recovery for persons remaining in vegetative (VS) and minimally conscious (MCS) states 3 to 12 months after severe TBI. The approach is to determine the neurobehavioral effect of rTMS, the relationship between neurobehavioral changes and net neural effects, and to identify and define the neural mechanisms related to neurobehavioral improvements by providing 30 active or placebo rTMS sessions.
Inclusion Criteria:
-Veteran of any combat era
-Both Genders
-20-65 years
-History of Post Traumatic Amnesia < 1 day for mild TBI; 1 day> x < 7days for moderate TBI))
-Ability to obtain a Motor Threshold (MT) will be determined during the screening process.
-If on a psychotropic medication regimen, that regimen will be stable for at least 4 weeks prior to entry to the study and patient will be willing to remain on a stable regimen during the acute treatment phase.
-Has an adequately stable condition and environment to enable attendance at scheduled clinic visits.
-For female participants, agrees to use one of the following acceptable methods of birth control: abstinence, oral contraceptive; Norplant
-Able to read, verbalize understanding, and voluntarily sign the Informed Consent Form prior to participating in any study-specific procedures or assessments.

Exclusion Criteria:
-Pregnant or lactating female.
-Unable to be safely withdraw, at least two-weeks prior to treatment commencement, from medications that substantially increase the risk of having seizures
-Have a cardiac pacemaker or a cochlear implant
-Have an implanted device (deep brain stimulation) or metal in the brain (see standard MRI exclusion criteria including metal screening section in telephone screen, Appendix A).
-Have a mass lesion, cerebral infarct or other active central nervous system (CNS) disease, including a seizure disorder.
-Known current psychosis as determined by DSM-IV coding in chart (Axis I, psychotic disorder, schizophrenia) or a history of a non-mood psychotic disorder.
-Diagnosis of Bipolar Affective Disorder (as determined by chart review and intake interview)
-Current amnesic disorders, dementia, mini mental state examination (MMSE) 24 or delirium.
-Current substance abuse (not including caffeine or nicotine) as determined by positive toxicology screen, or by history via AUDIT, within 3 months prior to screening
-Prior history of seizures
-Severe TBI or open head injury
-TBI within last two months or in acute stage
-Participation in another concurrent clinical trial
-Patients with prior exposure to rTMS/ECT
-Active current suicidal intent or plan. Patient at risk for suicide will be required to establish a written safety plan involving their primary psychiatrist and the treatment team before entering the clinical trial
Pape, Theresa L BenderPape, Theresa L Bender
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02366754 STU00103966
More Info
Copy

Evaluating the Circadian Response to Light in Delayed Sleep-Wake Phase Disorder

This study is looking at factors that contribute to the timing of sleep. Interested subjects will undergo screening to determine their sleep-wake habits, then will have an eye test and a blood draw. Participation will involve 2 outpatient visits, separated by up to 3 weeks of sleep-wake activity …
This study is looking at factors that contribute to the timing of sleep. Interested subjects will undergo screening to determine their sleep-wake habits, then will have an eye test and a blood draw. Participation will involve 2 outpatient visits, separated by up to 3 weeks of sleep-wake activity monitoring.
Individuals with delayed sleep-wake phase disorder and healthy controls
Abbott, Sabra MargaretAbbott, Sabra Margaret
  • Map it 201 E. Huron St.
    Chicago, IL
STU00203647
More Info
Copy

A wearable myoelectric-computer interface to reduce muscle co-activation in acute and chronic stroke

We are conducting a study investigating the use of small wearable devices, called myoelectric computer interfaces, to reduce abnormal arm muscle coordination in individuals with impaired arm movement from a stroke. Training will take place predominantly at home, with some sessions in the lab as well. This study could potentially …
We are conducting a study investigating the use of small wearable devices, called myoelectric computer interfaces, to reduce abnormal arm muscle coordination in individuals with impaired arm movement from a stroke. Training will take place predominantly at home, with some sessions in the lab as well. This study could potentially lead to improved arm function for stroke survivors who have abnormal arm coordination.

At least 18 years of age

- Had a stroke more than 6 months ago

- No large impairment in vision (glasses), memory, language or concentration

- Not currently participating in another research study on the arm

Slutzky, Marc WSlutzky, Marc W
  • Map it 355 E. Erie St.
    Chicago, IL
  • Map it 320 E. Superior Ave. Searle 11
    Chicago, IL
  • Map it 201 E. Huron St.
    Chicago, IL
STU00203644
More Info
Copy

Enroll-HD: A Prospective Registry Study in a Global Huntington’s Disease Cohort

The purpose of this research study is to collect clinical information about patients and their health. We will also collect biological samples, such as blood and DNA (the genetic material in your blood). Researchers will use this information and samples to learn more about HD and to try to find …
The purpose of this research study is to collect clinical information about patients and their health. We will also collect biological samples, such as blood and DNA (the genetic material in your blood). Researchers will use this information and samples to learn more about HD and to try to find new treatments for the disease. People from many countries contribute to Enroll-HD.
Individuals 18 yrs or older affected by Huntington's Disease (HD) or from a HD family or are a "community control" (a person who does not carry the HD genetic mutation that causes Huntington's disease and is not part of an HD family, but would like to participate in the study). Research visits are conducted yearly and will consists of a collection of medical and family history and biological samples.
Bega, DannyBega, Danny
  • Map it 675 N. St. Clair St. Suite 20-100
    Chicago, IL
STU00203021
More Info
Copy

The Role of Circadian Dysfunction in Hepatic Encephalopathy in Patients with Cirrhosis

Individuals with advanced liver disease (cirrhosis) often report new or worsening sleep problems. 
1) Diagnosis of end-stage liver disease or cirrhosis; 2) being evaluated for liver transplant; 3) Age >=18yo; 4) no severe kidney disease (for example, patients currently on dialysis are not eligible)
Kim, MinjeeKim, Minjee
  • Map it 201 E. Huron St.
    Chicago, IL
STU00204423
More Info
Copy

Clinical Research Consortium for the Study of Cerebellar Ataxia (CRC-SCA) to Study Natural History and Genetic Modifiers in Spinocerebellar Ataxia (SCA)

The purpose of this study is to collect natural history data among ataxia patients in a cohort of SCA 1, 2, 3, 6 patients using clinic-based neurological rating scales and performance measures. Another study goal is to identify new measures of ataxia, cognition, and neurobehavior in comparison to traditional …
The purpose of this study is to collect natural history data among ataxia patients in a cohort of SCA 1, 2, 3, 6 patients using clinic-based neurological rating scales and performance measures. Another study goal is to identify new measures of ataxia, cognition, and neurobehavior in comparison to traditional clinician rating methods. The gene analysis is expected to establish a relationship, if any, between age at onset of disease and disease progression rates.
• Age 18 and older
• Presence of symptoms and signs of ataxia
• Molecular diagnosis of SCA 1, 2, 3, 6 either in the participant or an affected family member
• Willingness to participate in the study and ability to give informed consent.
Opal, PuneetOpal, Puneet
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
NCT01060371 STU00204294
More Info
Copy

A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab (PRX002) in Participants with Early Parkinson’s Disease with a 6-Year All-Participants-On-Treatment Extension (PASADENA)

This is a multicenter, Phase II study to evaluate the effect of IV administration of RO7046015 in participants with early stage Parkinson's Disease (PD). Participants will be eligible if they have PD with bradykinesia plus one of the other cardinal signs of PD (resting tremor, rigidity) being present, without …
This is a multicenter, Phase II study to evaluate the effect of IV administration of RO7046015 in participants with early stage Parkinson's Disease (PD). Participants will be eligible if they have PD with bradykinesia plus one of the other cardinal signs of PD (resting tremor, rigidity) being present, without any other known or suspected cause of PD and are either untreated or treated with Azilect or Selegiline. The study will consist of two parts: a 52-week, treatment period of the study medication vs placebo (Part 1) after which eligible participants will continue into an all-participants-on-treatment (RO7046015) blinded to dose extension for an additional 52 weeks (Part 2).
*Men and women, aged 40 to 80 years inclusive, early PD , who were recently (< 2 years) diagnosed, and either untreated or treated with Azilect or Selegiline
Simuni, TatyanaSimuni, Tatyana
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
NCT03100149 STU00205125
More Info
Copy

Genetic causes and pathogenic mechanisms of adult epilepsies

The purpose of this study is to look at genetic markers of epilepsy in patients and their families using blood, saliva, skin, and brain tissue analysis.
Gerard, Elizabeth ErwayGerard, Elizabeth Erway
STU00205877
More Info
Copy

cIRB: Topiramate as a disease altering therapy for Cryptogenic Sensory Peripheral Neuropathy (CSPN)

This is a 96-week placebo-controlled trial of topiramate at a target dose of 100 mg daily (50 mg twice daily) as a potentially disease altering therapy for Cryptogenic Sensory Peripheral Neuropathy
INCLUSION: 1. Age 18-75; 2. Diagnosis of confirmed cryptogenic symptomatic distal symmetric peripheral polyneuropathy; 3. Prediabetes based on American Diabetes Association; 4. No history of prior therapy with topiramate; 5. Waist circumference >102 cm for men, >88 cm for women
Menichella, Daniela MMenichella, Daniela M
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
NCT02878798 STU00206049
More Info
Copy

Microburst VNS Therapy Feasibility Study in Subjects with Refractory Epilepsy

The purpose of this study is for patients with first-time implants of a Vagus Nerve Stimulator (VNS) to have the new Microburst stimulation settings optimized using fMRI scans.
Macken, Micheal PMacken, Micheal P
NCT01281293 STU00206259
More Info
Copy

cIRB: AtRial Cardiopathy and Antithrombotic Drugs In prevention After Crypotgenic Stroke

ARCADIA is a multicenter, biomarker-driven, randomized, double-blind, active-control, phase 3 clinical trial of apixaban versus aspirin in patients who have evidence of atrial cardiopathy and a recent stroke of unknown cause. Eleven hundred subjects will be recruited over 2.5 years at 120 sites in the NINDS …
ARCADIA is a multicenter, biomarker-driven, randomized, double-blind, active-control, phase 3 clinical trial of apixaban versus aspirin in patients who have evidence of atrial cardiopathy and a recent stroke of unknown cause. Eleven hundred subjects will be recruited over 2.5 years at 120 sites in the NINDS StrokeNet consortium. Subjects will be followed for a minimum of 1.5 years and a maximum of 4 years for the primary efficacy outcome of recurrent stroke and the primary safety outcomes of symptomatic intracranial hemorrhage and major hemorrhage other than intracranial hemorrhage.
Inclusion Criteria:

  • Age ≥ 45 years.
  • Clinical diagnosis of ischemic stroke + brain imaging to rule out hemorrhagic stroke.
  • Modified Rankin Scale (MRS) score ≤ 4.
  • Ability to be randomized within 3 to 120 days after stroke onset.
  • ESUS (embolic stroke of underdetermined source).
Exclusion Criteria:

  • History of atrial fibrillation
  • Clear indication for treatment-dose anticoagulant therapy, such as venous thromboembolism or a mechanical heart valve.
  • Need for antiplatelet agent other than aspirin, such as clopidogrel after implantation of a coronary artery stent.
  • History of spontaneous intracranial hemorrhage.
  • Chronic kidney disease with serum creatinine ≥2.5 mg/dL.

Caprio, Fan ZhangCaprio, Fan Zhang
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03192215 STU00206251
More Info
Copy

Clinical Trial Readiness for SCA1 and SCA3

Subjects must be 18-65 years of age with symptoms of ataxia or a diagnosis of SCA1 or SCA3 or have an affected family member. Subjects with a previous diagnosis of early stage SCA1 or SCA 3 may also be eligible. Subject must be able to undergo a MRI (brain …
Subjects must be 18-65 years of age with symptoms of ataxia or a diagnosis of SCA1 or SCA3 or have an affected family member. Subjects with a previous diagnosis of early stage SCA1 or SCA 3 may also be eligible. Subject must be able to undergo a MRI (brain scan) and not weigh over 300 lbs.
Subjects aged 18 to 65 with presence of symptomatic ataxic disease or asymptomatic mutation carrier or subjects with definite molecular diagnosis of SCA1 or SCA3 or another affected family member or Subjects of age >18 with previous diagnosis of early stage SCA1 and SCA3. Subjects must not make changes in physical/occupational therapy status within two months prior to enrollment. Subjects must not weigh over 300 lbs.
5) 6) No changes in sical/occupational therapy status within two months prior to enrolment
Opal, PuneetOpal, Puneet
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
NCT03487367 STU00206988
More Info
Copy

A Phase 3, Randomized, Rater-Blinded, Multi-Center Study to Evaluate the Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Patients with Wilson Disease Aged 12 Years and Older with an Extension Period of Up to 60 Months

The primary objective of this study is to evaluate the efficacy of the drug WTX101 administered for 48 weeks, compared to standard of care (SoC), on copper (Cu) control in subjects with Wilson's disease aged 18 and older.…
The primary objective of this study is to evaluate the efficacy of the drug WTX101 administered for 48 weeks, compared to standard of care (SoC), on copper (Cu) control in subjects with Wilson's disease aged 18 and older.
Diagnosis of Wilson's Disease, Treatment for >28 days with chelation therapy, Zn therapy or a combination of chelator and Zn; willing to avoid the use of vitamins and/or minerals containing CU, Zn or Mo throughout the study, willing to undergo > 48-hour washout from current WD treatment
Bega, DannyBega, Danny
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
NCT03403205 STU00206921
More Info
Copy

Gut Microbial remodeling with Resistant Maltodextrin for motor and non-motor symptoms in Parkinson's disease: safety and tolerability study.

The objective of this study is to examine thesafety and tolerability of resistant maltodextrin (RM), a prebioticnon-digestible fiber, and its effect on the gut microbiome, as well as motor and non-motorsymptoms, in Parkinson's Disease.We will conduct a randomized, parallel-groupdouble-blinded controlled trial assessing resistant maltodextrin …
The objective of this study is to examine thesafety and tolerability of resistant maltodextrin (RM), a prebioticnon-digestible fiber, and its effect on the gut microbiome, as well as motor and non-motorsymptoms, in Parkinson's Disease.

We will conduct a randomized, parallel-groupdouble-blinded controlled trial assessing resistant maltodextrin to placebo. You will be randomized (like a coin flip) toreceive either resistant maltodextrin or maltodextrin to take once a day in themorning for 4 weeks.

Participation in this research study lasts 6-7 weeks and includes 3 in-person visits and 4 phone assessments.

You may be eligible if you:

  • are ≥ 60 years
  • have been diagnosed with Parkinson's Disease
  • have NOT been diagnosed with diabetes
  • are not currently taking any probiotics or laxatives
  • Malkani, Roneil GopalMalkani, Roneil Gopal
    NCT03667404 STU00207142
    More Info
    Copy

    Radicava® (Edaravone) Biomarker Study in Participants with Amyotrophic Lateral Sclerosis

    This is a non-interventional (no study drug), observational study of patients with ALS who elect to begin treatment with Edaravone (radicava).This study is designed to investigate a selected panel of biomarkers in patients with ALS, treated with Edaravone. Biomarkers of oxidative stress, inflammation and neurodegeneration will be explored. …

    This is a non-interventional (no study drug), observational study of patients with ALS who elect to begin treatment with Edaravone (radicava).

    This study is designed to investigate a selected panel of biomarkers in patients with ALS, treated with Edaravone. Biomarkers of oxidative stress, inflammation and neurodegeneration will be explored. Epigenetic and protein biomarkers will also be investigated.

    Edaravone will NOT be provided by the study sponsor.

    1. Sporadic or familial ALS diagnosed as possible, probable, probable-laboratory supported or definite as defined by the World Federation of Neurology revised El Escorial criteria

    2. Decision made to prescribe Edaravone prior to screening

    3. Participant will likely be able to obtain commercial Edaravone and likely to complete 6 cycles of treatment, per site investigator estimation

    4. Participant either naïve to Edaravone or who did not receive any Edaravone dose within 28 days prior to screening

    5. Participant with a contraindication to Edaravone may not participate

    6. Participant is participating in an interventional clinical trial may not participate

    Ajroud-Driss, SendaAjroud-Driss, Senda
    • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
      Chicago, IL
    NCT04259255 STU00210057
    More Info
    Copy

    Natural history study of ALS and other motor neuron disorders

    This is one of the largest non-interventional observational study of patients with ALS and other motor neuron disorders. It is both prospective and retrospective. It does not require blood sampling.

    1. A clinical diagnosis of El Escorial of suspected, possible, probable, or definite ALS.

    2. Other motor neuron disorders, including but not limited to spinobulbar muscular atrophy (SBMA, Kennedy’s disease), Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA), and Progressive Bulbar Palsy (PBP).

    3. Excluded are any disease that does not meet criteria for any motor neuron disorder

    Ajroud-Driss, SendaAjroud-Driss, Senda
    • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
      Chicago, IL
    STU00209860
    More Info
    Copy

    AtRial Cardiopathy and Antithrombotic Drugs In prevention After Crypotgenic Stroke- Cognition and Silent Infarcts

    ARCADIA-CSI an ancillary study to the ARCADIA trial in which we will assess cognitive function and silent infarcts in a subset of the ARCADIA population. The purpose of ARCADIA-CSI is to determine the effect of apixaban vs aspirin on these two additional outcomes in patients with stroke …
    ARCADIA-CSI an ancillary study to the ARCADIA trial in which we will assess cognitive function and silent infarcts in a subset of the ARCADIA population. The purpose of ARCADIA-CSI is to determine the effect of apixaban vs aspirin on these two additional outcomes in patients with stroke of unknown cause and atrial cardiopathy.
    Patients randomized in the ARCADIA trial and on study drug will be eligible for ARCADIA-CSI if they can undergo cognitive testing (english speaking) and have no MRI contraindications.
    Caprio, Fan ZhangCaprio, Fan Zhang
    • Map it 201 E. Huron St.
      Chicago, IL
    • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
      Chicago, IL
    NCT03192215 STU00211262
    More Info
    Copy

    MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study (MASTERS-2) (Protocol #: B01-04)

    A Phase 3 study to examine the safety and effectiveness of the allogeneic, adult stem cell investigational product, MultiStem®, in adults who have suffered an acute ischemic stroke in the previous 18-36 hours.…
    A Phase 3 study to examine the safety and effectiveness of the allogeneic, adult stem cell investigational product, MultiStem®, in adults who have suffered an acute ischemic stroke in the previous 18-36 hours.

    Primary Inclusion Criteria:

    • Male or female subjects ≥18 years of age
    • Clinical diagnosis of ischemic stroke involving cerebral cortex
    • Onset of stroke symptoms must have occurred 18 to 36 hours prior to the planned start of administration of the investigational product
    • Occurrence of a moderate to moderately severe stroke with a persistent neurologic deficit documented by a NIHSS score of 8 to 20 (inclusive) that does not change by ≥4 points during the initial screening period
    • A mRS score of 0 or 1 prior to the onset of symptoms of the current stroke

    Primary Exclusion Criteria:

    • Presence of a lacunar or a brainstem infarct
    • Comatose state
    • Brain hemorrhage
    • Major neurological event such as stroke or clinically significant head trauma within 6 months of enrollment into the study

    Batra, AyushBatra, Ayush
    • Map it 201 E. Huron St.
      Chicago, IL
    • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
      Chicago, IL
    NCT03545607 STU00209969
    More Info
    Copy

    A Phase 1 Single- and Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB094 Administered Intrathecally to Adults With Parkinson’s Disease (Protocol# 254PD101)

    The purpose of study is to determine whether BIIB094 may improve PD symptoms in subjects with or without changes in the LRRK2 gene. The study medication will be given as an injection into your back near the spinal cord. This iscalled an “intrathecal” injection.…
    The purpose of study is to determine whether BIIB094 may improve PD symptoms in subjects with or without changes in the LRRK2 gene. The study medication will be given as an injection into your back near the spinal cord. This iscalled an “intrathecal” injection.

    2. Diagnosis of PD w/in 7yrs without motor fluctuationsor dyskinesia.

    3. Not on any medication for PD or on stable therapy for 8weeks prior to screening.

    Simuni, TatyanaSimuni, Tatyana
    • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
      Chicago, IL
    NCT03976349 STU00210196
    More Info
    Copy

    Oxidative Markers and Efficacy in ALS/MND Phenotypes Treated with Edaravone

    We are only recruiting patients who have not started their edaravone treatment.

    Location of study: Les Turner ALS Center at Northwestern Medicine, 259 E. Erie St., Lavin 19, Chicago, IL 60611.

    Inclusion:

    Either possible, probable, or definite ALS,predominantly lower motor neuron disease Predominantly upper motor neuron disease, orbulbar

    With or without cognitive involvement

    Willing to participate

    On no experimental treatment

    Ages 18 - 85

    No prior exposure to Radicava

    On a stable dose of riluzole for 30 days or offriluzole

    Male or female

    Females of childbearing age must usecontraception

    Exclusion:

    Unstable medical illness

    Abnormal liver function (>2x ULN)

    Unlikely to survive for at least 26 weeks

    Ajroud-Driss, SendaAjroud-Driss, Senda
    • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
      Chicago, IL
    NCT04097158 STU00211350
    More Info
    Copy

    A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients with Parkinson’s Disease with at Least One GBA1 Mutation (PROPEL, Protocol #: J3Z-MC-OJAA previously called PRV-PD101)

    PR001A is an investigational gene therapy product that is being developed for the treatment of PD in patients with GBA1 mutations. The purpose of this study is to find out what effects PR001A has on Parkinson’s disease patients. Participants will be assigned to receive one dose of PR001A by …
    PR001A is an investigational gene therapy product that is being developed for the treatment of PD in patients with GBA1 mutations. The purpose of this study is to find out what effects PR001A has on Parkinson’s disease patients. Participants will be assigned to receive one dose of PR001A by injection into the cisterna magna (a large space at the base of the brain).

    1. 40-75 years of age.

    2. Diagnosis of PD with H&Y 3-4.

    3. On stable PD therapy for 8 weeks prior to baseline.

    4. At least 1 GBA gene mutation.

    Simuni, TatyanaSimuni, Tatyana
    • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
      Chicago, IL
    NCT04127578 STU00209947
    More Info
    Copy

    Platform Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS): A perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.

    In this trial, multiple investigational products for ALS will be tested simultaneously or sequentially. Each investigational product will be tested in a regimen. Each regimen consists of a placebo-controlled trial, meaning that the active investigational product and matching placebo will be tested in each regimen.The additional details that …

    In this trial, multiple investigational products for ALS will be tested simultaneously or sequentially. Each investigational product will be tested in a regimen. Each regimen consists of a placebo-controlled trial, meaning that the active investigational product and matching placebo will be tested in each regimen.

    The additional details that govern the testing of each investigational product will be summarized in separate regimen-specific appendices (RSAs). Each regimen will have a separate ClinicalTrials.gov posting, which will include specific information about the regimen. All regimen-specific outcome measures will be detailed in each regimen posting.

    Participants will have an equal chance to be randomized to all regimens that are active at the time of screening. Once randomized to a regimen, participants will be randomized in a 3:1 ratio to either study drug or placebo.

    The following regimens are active in the trial:

    Regimen A - Zilucoplan Regimen B - Verdiperstat Regimen C - CNM-Au8 Regimen D - Pridopidine Regimen E - Trehalose

    New regimens will be continuously added as new investigational products become available. The HEALEY ALS Platform Trial will enroll additional participants as each new regimen is available.

    The basic eligibility criteria include:

    1. Onset of ALS WEAKNESS within the last 3 years.

    2. FVC (breathing test) > 50%

    3. If on riluzole, must be on a stable dose for 30 days. Must not start riluzole during the study.

    4. If on radicava, must be on a stable dose for 30 days. Must not start riluzole during the study.

    5. Must be able to swallow for the next 6 months

    6. No history stem cell treatment

    7. No history of cancer within the last 5 years

    Ajroud-Driss, SendaAjroud-Driss, Senda
    • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
      Chicago, IL
    NCT04297683 STU00212680
    More Info
    ALS Platform
    Copy

    Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment with NLY01 in Early-stage Parkinson’s Disease

    The purpose of study is to determine if NLY01 helps lessen symptoms and signs of early Parkinson’s disease and whether it slows the progression of Parkinson’s disease.…
    The purpose of study is to determine if NLY01 helps lessen symptoms and signs of early Parkinson’s disease and whether it slows the progression of Parkinson’s disease.

    1. Subjects aged 30-80 yrs of age

    2. Lessthan 5 yrs of PD symptom onset

    3. Must not be taking any medication for PD treatment

    Simuni, TatyanaSimuni, Tatyana
    • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
      Chicago, IL
    NCT04154072 STU00211693
    More Info
    Copy

    Use of Glenohumeral Injections for Management of Shoulder Pain in Individuals with ALS

    The purpose of this study is to develop a practice for measuring the efficacy of ultrasound-guided shoulder joint injections in patients with ALS who have exhibited shoulder pain and/or adhesive capsulitis. Patients will receive corticosteroid injections as part of their normal or standard care for shoulder pain in …
    The purpose of this study is to develop a practice for measuring the efficacy of ultrasound-guided shoulder joint injections in patients with ALS who have exhibited shoulder pain and/or adhesive capsulitis. Patients will receive corticosteroid injections as part of their normal or standard care for shoulder pain in ALS (not provided by the study). They will then be asked to complete questionnaires at Baseline and over the phone over approximately 3 months. 
    1. Diagnosed with ALS

    2. Being referred for evaluation for glenohumeral shoulder injections for management of shoulder pain

    3. Able to utilize written, typed or verbal communication, independently or with the assistance of a caregiver

    4. Able to understand study procedures, answer questionnaires, and provide informed consent

    Franz, Colin KFranz, Colin K
    • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
      Chicago, IL
    STU00213465
    More Info
    Copy

    A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients with Early Stage of Huntington Disease

    The purpose of this study is to evaluate the safety and effectiveness of the study drug, pridopidine,on everyday functioning and daily activities, as well as movement and behaviorin participants with early stage Huntington Disease (HD)…
    The purpose of this study is to evaluate the safety and effectiveness of the study drug, pridopidine,on everyday functioning and daily activities, as well as movement and behaviorin participants with early stage Huntington Disease (HD)

    1. >25yrs of age.

    2. Diagnosis of HD with CAG repeat > 36

    Bega, DannyBega, Danny
    • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
      Chicago, IL
    NCT04556656 STU00213780
    More Info
    Copy

    A multicenter, double-blind, randomized study to evaluate the effects of tasimelteon vs. placebo in participants with Delayed Sleep-Wake Phase Disorder (DSWPD)

    The purpose of this study is to evaluate the effect of aninvestigational drug called tasimelteon on the sleep-wake cycle of patientswith Delayed Sleep-Wake Phase Disorder (DSWPD) and to assess the safety oftasimelteon. Participants in this study will randomly be assigned totasimelteon or placebo, to take over a period …

    The purpose of this study is to evaluate the effect of aninvestigational drug called tasimelteon on the sleep-wake cycle of patientswith Delayed Sleep-Wake Phase Disorder (DSWPD) and to assess the safety oftasimelteon. Participants in this study will randomly be assigned totasimelteon or placebo, to take over a period of 35 days. During this time,participants will be required to go to bed at certain fixed times and keep anelectronic daily sleep diary. Additionally, there will be 4 visits to yourstudy doctor's clinic, where you will be assessed for eligibility and safety.At the clinic, your study doctor will perform a physical examination, blooddraws, heart tests, questionnaires, and test your urine for drugs and alcohol.You will not be charged for any of these procedures and you may be compensatedfor your time.

    If you complete the initial 35 days of the study, you willhave the option of receiving treatment with tasimelteon for up to 11 monthsafter. No matter which treatment you were randomly assigned during the first 35days, tasimelteon or placebo, you will receive tasimelteon during theadditional 11 months, if you choose to continue. During those 11 months, therewill be 4 additional visits to your study doctor's clinic (spaced 60-90 daysapart) to assess your health and safety.

    • Inclusion Criteria:

      • Ability and acceptance to provide written informed consent of the participant or legal guardian. Participants ≥ 16 and < 18 years of age will also need to provide written assent.
      • A confirmed clinical diagnosis of Delayed Sleep-Wake Phase Disorder (DSWPD).
      • Men or women between 16 - 65 years, inclusive.
      • Body Mass Index (BMI) of ≥ 18 and ≤ 30 kg/m^2.

    • Exclusion Criteria:
      • History of psychiatric disorders within 12 months.
      • Major surgery, trauma, illness, general anesthesia, or immobility for 3 or more days within the last 30 days.
      • Pregnancy, recent pregnancy (within 6 weeks), or women who are breastfeeding.
      • A positive test for substances of abuse
    Zee, Phyllis CZee, Phyllis C
    • Map it 676 N. Saint Clair St. Seventh Floor, Suite 701
      Chicago, IL
    • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
      Chicago, IL
    NCT04652882 STU00213922
    More Info
    Copy

    A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo in combination with Riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)

    This is a phase 3, placebo-controlled, study comparing the safety and efficacy of two doses of MASITINIB (4.5 mg and 6.0 mg) and riluzole vs. placebo and riluzole over 48 weeks. …
    This is a phase 3, placebo-controlled, study comparing the safety and efficacy of two doses of MASITINIB (4.5 mg and 6.0 mg) and riluzole vs. placebo and riluzole over 48 weeks. 
    Basic Inclusion/ Exclusion criteria:

  • Patient treated with stable dose of riluzole for 3 months
  • Patient able to obtain riluzole through insurance and remain on riluzole throughout the study
  • Disease duration (weakness) from diagnosis less than 24 months
  • Must have a sub-score of at least 2 on every sub-section of the ALSFRS-R
  • FVC over 60%
  • Ajroud-Driss, SendaAjroud-Driss, Senda
    • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
      Chicago, IL
    NCT02588677 STU00213943
    More Info
    Copy

    A Phase 3b, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for a Period of 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)

    This is a phase 3b, randomized, study evaluating the safety and efficacy of ORAL EDARAVONE/ RADICAVA administered over 48 weeks. Eligible participants are randomized to two groups with different dosing schemes.…
    This is a phase 3b, randomized, study evaluating the safety and efficacy of ORAL EDARAVONE/ RADICAVA administered over 48 weeks. Eligible participants are randomized to two groups with different dosing schemes.
    Basic Inclusion/ Exclusion criteria:

  • No prior use of radicava/edaravone
  • ALS weakness onset within the last 2 years
  • FVC over 70%
  • Must score at least a 2 on each sub-section of the ALSFRS-R
  • El Escorial scored Probable or Definite ALS
  • Ajroud-Driss, SendaAjroud-Driss, Senda
    • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
      Chicago, IL
    NCT04165824 STU00213716
    More Info
    Copy

    A Double-Blind Placebo-Controlled, Randomized 18-Month Phase 2A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinectics of Oral UCB0599 in Study Participants with Early Parkinson’s Disease

    This study is for people with early-stage Parkinson's disease. The objective of this study is to find out whether UCB0599, an investigational medication, can slow down the progression of PD. This study also tests whether UCB0599 is safe and tolerable. This study is placebo-controlled and will last …

    This study is for people with early-stage Parkinson's disease. The objective of this study is to find out whether UCB0599, an investigational medication, can slow down the progression of PD. This study also tests whether UCB0599 is safe and tolerable. This study is placebo-controlled and will last about 21 months. If you join the study, you will have regular scheduled appointments with the study staff and will have medical procedures and tests during these visits, like imaging studies, body function tests, and questionnaires.

    You might be a candidate for this study if:

    • You are 40 - 75 years old
    • You have been diagnosed with Parkinson disease within the last two years
    • You have only mild symptoms of PD, like slowness of movement, muscle stiffness / rigidity, or tremor / shaking

    There are additional eligibility criteria that will be discussed with you.

    Akhtar, Rizwan SmeerAkhtar, Rizwan Smeer
    • Map it 259 E. Erie St. Nineteenth Floor
      Chicago, IL
    NCT04658186 STU00214389
    More Info
    Copy

    Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects with Wilson Disease

    Given the limited information on the frequency and spectrum of disease manifestations and clinical course of Wilson disease, this study aims to assess the utility and feasibility of various assessments and biomarkers to inform endpoint selection for future clinical studies, better understand the relationship between biomarkers and potential clinical outcomes, …

    Given the limited information on the frequency and spectrum of disease manifestations and clinical course of Wilson disease, this study aims to assess the utility and feasibility of various assessments and biomarkers to inform endpoint selection for future clinical studies, better understand the relationship between biomarkers and potential clinical outcomes, and characterize the clinical presentation of Wilson disease.

    UX701-CL001 is a clinical survey study for subjects with a confirmed diagnosis of Wilson disease (Figure 1). Subjects will complete assessments at the study site and at home to evaluate the clinical manifestations of Wilson disease in clinical and real-world environments. The study includes general assessments; patient- and clinician-reported outcome (PRO and CRO)

    Bega, DannyBega, Danny
    NCT04531189 STU00212962
    More Info
    Copy

    A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety of Engensis in Participants with Amyotrophic Lateral Sclerosis

    This is a phase 2, placebo-controlled, study assessing the safety of ENGENSIS. Participants will be randomized to study drug (66%) or placebo (34%). This study drug or placebo is administered via intramuscular injections. 128 injections are administered in different parts of the body on one treatment day. There …
    This is a phase 2, placebo-controlled, study assessing the safety of ENGENSIS. Participants will be randomized to study drug (66%) or placebo (34%). This study drug or placebo is administered via intramuscular injections. 128 injections are administered in different parts of the body on one treatment day. There are 6 treatment days when the study drug or placebo is administered. The study lasts approximately 6 months.
    Basic Inclusion/ Exclusion criteria:

  • Onset of ALS weakness within the last 4 years
  • SVC over 50%
  • Stable dose of riluzole for 1 month, or not start during study
  • Stable dose of radicava for 1 month, or not start during study
  • Limb onset of ALS required
  • No personal history of cancer within the last 3 years
  • Ajroud-Driss, SendaAjroud-Driss, Senda
    • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
      Chicago, IL
    NCT04632225 STU00214139
    More Info
    ALS Engensis
    Copy

    PLS Natural History Study (PNHS)

    This is a non-interventional (no study drug), natural history study of patient with primary lateral sclerosis (PLS). The purpose of this study is to to develop a natural history dataset and biorepository of early PLS and well-established PLS cases for future clinical trials. The study will also evaluate …

    This is a non-interventional (no study drug), natural history study of patient with primary lateral sclerosis (PLS).

    The purpose of this study is to to develop a natural history dataset and biorepository of early PLS and well-established PLS cases for future clinical trials. The study will also evaluate differences in disease progression in early PLS and well-established PLS cases.

    Patients will be enrolled over 24 months and complete assessments in person and over the phone.

    Some of the BASIC, but not full, list of eligibility criteria are below:

    1. PLS diagnosis is based on the new PLS diagnostic criteria

    2. Symptom onset was no more than 15 years prior to baseline

    3. Ability to independently walk with or without an assistive device (e.g., walker) at the baseline evaluation

    4. Some bulbar symptoms (dysarthria, dysphagia, drooling or pseudobulbar affect)

    5. UMN symptoms and signs in a region other than the legs

    Ajroud-Driss, SendaAjroud-Driss, Senda
    • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
      Chicago, IL
    STU00214272
    More Info
    Copy

    Web-based Automated Imaging Differentiation of Parkinsonism

    This study is for people who have Parkinson's disease (PD), multiple system atrophy (MSA), or progressive supranuclear palsy (PSP). The objective of this study is to find out whether an advanced imaging study can distinguish people with PD, MSA, or PSP from one another. The imaging study uses a …

    This study is for people who have Parkinson's disease (PD), multiple system atrophy (MSA), or progressive supranuclear palsy (PSP). The objective of this study is to find out whether an advanced imaging study can distinguish people with PD, MSA, or PSP from one another. The imaging study uses a brain MRI (without dye or contrast) along with a web-based automated software tool that analyzes the MRI data automatically. The study requires two visits, one at the start and one 12-18 months later. The MRI is only performed at the first visit. At each visit, there are assessments of movement and thinking, along with several questionnaires.

    • Age of 40 - 80 years
    • Ability to have a brain MRI scan
    • Clinical diagnosis of Parkinson disease at least 5 years ago, or
    • Clinical diagnosis of multiple systems atrophy (parkinsonian type), or
    • Clinical diagnosis of progressive supranuclear palsy
    Akhtar, Rizwan SmeerAkhtar, Rizwan Smeer
    • Map it 259 E. Erie St. Nineteenth Floor
      Chicago, IL
    STU00214779
    More Info
    Copy

    An Intermediate-Size Expanded Access Protocol for Amyotrophic Lateral Sclerosis with Verdiperstat (BHV-3241)

    The primary objective of this intermediate-size Expanded Access Protocol (EAP) is to provide access to investigational product verdiperstat for participants with ALS who do not qualify for the HEALEY ALS Platform Trial.…
    The primary objective of this intermediate-size Expanded Access Protocol (EAP) is to provide access to investigational product verdiperstat for participants with ALS who do not qualify for the HEALEY ALS Platform Trial.

    The BASIC, but not full, list of eligibility criteria are below:

    1. Sporadic or familial ALS diagnosed as suspected, possible, probable, lab-supported probable, or definite ALS defined by El Escorial criteria

    2. Age 18 years or older

    3. Participant must be unable to participate in the HEALEY ALS Platform Trial

    4. Participants have established care with a physician at the specialized ALS center involved in the protocol and will maintain this clinical care throughout the duration of the EAP

    5. Participants must have the ability to swallow whole pills without crushing or chewing

    6. Participants who are enrolled in another EAP or a Clinical Trial

    Ajroud-Driss, SendaAjroud-Driss, Senda
    • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
      Chicago, IL
    NCT04081714 STU00215197
    More Info
    Copy

    A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

    Tofersen (also called BIIB067) is currently being evaluated for the treatment of adults with familial ALS associated with a mutation in the SOD1 gene. The optimal timing for initiation (i.e., prior to or after the emergence of clinically manifested disease) of tofersen is unknown. This study will evaluate the …

    Tofersen (also called BIIB067) is currently being evaluated for the treatment of adults with familial ALS associated with a mutation in the SOD1 gene. The optimal timing for initiation (i.e., prior to or after the emergence of clinically manifested disease) of tofersen is unknown. This study will evaluate the impact of initiating tofersen based on biomarker evidence of disease activity, prior to the emergence of clinical symptoms or signs that definitively indicate ALS.

    There are four parts to this study, each with different eligibility criteria. Please contact the study coordinator and he/she will determine whether you are eligible. In order to enroll in the study (Part A), here are a few basic (but not complete) eligibility criteria:

    1. 18 years or older

    2. Must have one of the following SOD1 mutations confirmed by a central reader. Please contact the study coordinator for a complete list.

    3. If a SOD1 mutation is not listed, your mutation will be adjudicated by a Mutation Adjudication Committee.

    4. Plasma neurofilament (NfL) level less than 44 pg/mL during Screening

    5. Clinically pre-symptomatic for ALS (i.e., must not have clinically manifested ALS) at Part A Screening Visit

    6. History or positive test result at Screening for HIV, Hep-B, or Hep-C

    Ajroud-Driss, SendaAjroud-Driss, Senda
    • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
      Chicago, IL
    NCT04856982 STU00214617
    More Info
    Copy

    Evaluation of digital technologies for home-based assessment of ALS patients

    This is a non-interventional study (no study drug). We are measuring home-based digital assessments. The purpose of this study is to evaluate the feasibility, patient-acceptability, adherence and validity of home-based collection of digital measures that are relevant to the assessment of disease in ALS patients. The …

    This is a non-interventional study (no study drug). We are measuring home-based digital assessments.

    The purpose of this study is to evaluate the feasibility, patient-acceptability, adherence and validity of home-based collection of digital measures that are relevant to the assessment of disease in ALS patients. The goal of this study is to determine which home-based digital measurements are reliable predictors of change in ALS status, when compared to the conventional scale, the ALSFRSR.

    1. Non-ventilator dependent at the screening visit.

    2. Able to ambulate short distances (at least 3 m) with or without walking aid.

    3. Able to grasp a pen and able to write

    4. For the dedicated C9orf72 group only (10-15 participants) presence of a C9orf72 repeat expansion.

    5. Having a study partner who agrees to participate in the study and who is intellectually, visually, and verbally capable, and fluent in, and able to read, the language in which study assessments are administered.

    Ajroud-Driss, SendaAjroud-Driss, Senda
    • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
      Chicago, IL
    NCT00000419 STU00215205
    More Info
    ALS BASICHR0053
    Copy

    A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY PARKINSON'S DISEASE

    This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.…
    This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.

    • Diagnosis of PD for at least 6 months to maximum 3 years at screening and between 50-85 years of age

    • On symptomatic PD medication for at least 6 months, with a stable dose for 3 months prior to baseline

    • No dyskinesisa or motor fluctuations (i.e. MDS-UPDRS Part IV = 0)

    Larson, Danielle NicoleLarson, Danielle Nicole
    NCT04777331 STU00214429
    More Info
    Copy

    Follow Neurology on